Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Фаза 2
Прекращено
NCT05167409
| Заболевание | Microsatellite Stable Metastatic Colorectal Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | University of Colorado, Denver |
|---|
| Статус | Прекращено |
|---|
| Участники | 19 участн. |
|---|
| Вмешательство | Evorpacept (ALX148), Cetuximab, Pembrolizumab |
|---|
| Дата начала | 28.07.2022 |
|---|
| Дата завершения | 30.10.2024 |
|---|
| Публикация результатов | 22.07.2026 |
|---|
Кратко
This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Objective Response Rate (ORR)
The duration of time during which tumor assessments were performed for each individual patient. Per protocol, assessments will continue until disease progression. The latest assessment was performed at Cycle 21, Day 15 (14.5 mo after informed consent) · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 1 Participants |
|---|
Determine the Recommended Dose (RD) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab
During the safety run-in, each patient must have completed at least the 1st cycle (3 weeks) of treatment. · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 1 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 0 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.